What is Sangamo Therapeutics Inc?
, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 30.66M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.